. 2007 Dec;3(6):1029–1037.

Table 3.

Results from two repeated measures linear mixed effects regression models examining the influence of eGFR and albuminuria on systolic and diastolic blood pressure (BP) response^*

Covariate	Systolic blood pressure response			Diastolic blood pressure response

	Estimate^{^}	95% CI	p-value	Estimate^{^}	95% CI	p-value
Age (years)	−0.28	−0.43, −0.13	<0.001	0.08	−0.01, 0.17	0.11
Male gender	−1.14	−5.04, 2.76	0.57	−0.38	−2.36, 1.94	0.75
African American race	−5.11	−11.33, 1.11	0.11	−2.83	−6.75, 1.09	0.16
Diabetes	−5.68	−9.55, −1.81	0.004	−0.89	−3.31, 1.53	0.47
BMI > 30 kg/m²	−3.71	−7.00, −0.42	0.027	−1.48	−3.58, 0.62	0.17
Difference from SBP or DBP goal at baseline	0.68	0.61, 0.75	<0.001	0.51	0.43, 0.59	<0.001
Therapeutic intensity score^#	2.09	0.95, 3.23	<0.001	1.27	0.50, 1.34	0.001
eGFR < 60 ml/min/1.73 m²	−8.44	−12.63, −4.25	<0.001	−4.48	−7.12, −1.84	<0.001
Albuminuria status^†:
Macro-albuminuria	−10.32	−15.28, −5.36	<0.001	−7.88	−11.14, −4.62	<0.001
Micro-albuminuria	−5.08	−8.63, −1.55	0.005	−3.88	−6.18, −1.58	0.001

Note: Visit-specific change in BP from baseline (baseline BP minus visit-specific BP calculated at each post-baseline visit).

^†

With normal albumin as reference. Normal = <30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria = >300 mg/g creatinine.

Visit-specific anti-hypertension therapeutic intensity score: calculated as daily dose/maximum FDA approved dose, summed across medication class.

^{^}

Estimate (beta coefficient) deviation from expected (mean [intercept]) BP response in mmHg for participants with this characteristic compared to those without, given inclusion of all other variables in adjusted model. Positive values indicate greater reductions in BP.

Abbreviations: eGFR, estimated glomerular fi ltration rate; BMI, body mass index; BP, blood pressure.